

Targeting of drugs for cancer therapy
Chairperson: Dr Klaus Bosslet

- 8.00 Armed Antibodies Targeting Tumor Antigens: Selecting the Right Tool for the Job.
Dr James Legg, Senior Scientist, Medimmune, UK.
- 8.20 RG7787 - A cytolytic fusion protein based on a de-immunised variant of Pseudomonas Exotoxin (PE)
Dr Klaus Bosslet, Head Discovery Oncology Penzberg, Roche Diagnostics GmbH, Germany
- 8.40 Preclinical profile and CMC properties of SYD985 – A novel HER2-targeting ADC.
Dr Ruud Coumans, Project Leader, Synthon, The Netherlands.
- 9.00 Pretargeted radioimmunoimaging and – therapy: from mice to men'.
Professor dr Otto Boerman, Head Preclinical Research, Radboud University Medical Center, The Netherlands.
- 9.20 Antibody Drug Conjugates (ADCs) Utilizing Maytansinoid Technology: From Bench to Kadcyla and Beyond.-
Dr John M. Lambert, Executive VP and CSO, ImmunoGen, Inc., USA.

Novel Therapeutic Antibodies
Chairperson: Dr Volker Schellenberger

- 9.40 ARGX-110, a clinical stage, neutralizing, humanized monoclonal antibody to the human CD70 antigen with enhanced.
Dr Karen Silence, arGEN-X BVBA, Belgium.
- 10.00 ARGX-111, a defucosylated antagonistic anti-MET antibody, displays potent anti-tumor activity through enhanced
Dr Michael Saunders, Senior Director Targets and Programmer, arGEN-X BVBA, Belgium.
- 10.20 Comprehensive functional screening of the CLL surfaceome identifies FcγRIIb as a promising target, and FcγRIIb-blocking antibodies modulate antibody therapy in vivo.
Dr Bjorn Frendeus, CSO, Bioinvent International (Publ) Sweden.
- 10.40 Refreshments and Networking
- 11.00 Using antibody fragments to assist structural biology, for intracellular vaccination and for drug discovery.
Professor Terrence H. Rabbitts, MRV, University of Oxford, UK.

- 11.20 Novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key driver of metastasis and a mechanism of drug-resistance.
Dr Sergej M. Kiprijanov, Director of Biologics Research and Development, BerGenBio, Norway.
- 11.40 Human monoclonal antibodies against cancer related proteins – an update
Dr Dimiter S. Dimitrov, NCI/NIH, USA.
- 12.00 Strategies for enhancing the efficacy of HER2-targeted anti-cancer therapies'
Dr Gail Lewis Phillips, Senior Scientist, Genentech, Inc., USA.

Future advances in novel biologics platform
Chairperson: Dr Mike Romanos

- 12.20 The application of nanotechnology to radioimmunotherapy and radioimmunodiagnostics.
Professor Katherine A. Vallis, Department of Oncology, University of Oxford, UK.
- 12.40 Title to be announced.
Dr Louis Boon, CSO, Bioceros, The Netherlands.
- 1.00 Lunch
- 2.00 Combining Phage and Yeast-Display: New developments in Antibody Discovery and Optimisation
Dr Vera Malkenthin, Chief Scientist, ABCheck S.r.o. Pizen. Czech Republic.
- 2.20 Use of molecular imaging with monoclonal antibodies in drug development.
Professor. Elisabeth E.G.E.de Vries, Department of Oncology, University of Groningen, The Netherlands.
- 2.40 Preliminary pharmacologic characterization of GSK2849330, a monoclonal AccretaMab® antibody with optimized ADCC and CDC activity directed against HER3.
Dr Neil Clarke, Director, Biopharm Discovery Group, RD Biopharm, R&D, GSK, UK.

Contact

Dr. G. Subramanian, 44 Oaken Grove, Maidenhead, Berkshire, SL6 6HH, UK
Tel: +44 (0) 7960 139108
Fax: +44 (0) 1628 671448
Email: gsub@subramanian.org.uk
Web: www.subramanian.org.uk



Produced by Hayward Design & Print • www.hayward-design.co.uk



WORLD BIOPHARM FORUM
2014

NEW DEVELOPMENTS IN CANCER BIOLOGICS

Robinson College, Cambridge, UK
29-30th September, 2014



Sponsors:



www.subramanian.org.uk

To reserve your place please complete the registration form in BLOCK LETTERS and **post** it with full remittance to: Dr. G. Subramanian, 44 Oaken Grove, Maidenhead, Berkshire, SL6 6HH or, **email** to gsub@subramanian.org.uk

Full Name:

Job Title:

Organisation:

Address:

.....

.....Postcode:

Country:

Tel:

Email:

Any Special Requirement (Dietary):

Questions or Comments:

.....

Registration Fees:

Full attendance including all meals and accommodation: **£700**

Attendance with all meals and no accommodation: **£575**

Method of payment:

Cheques payable to Dr. G. Subramanian in Pound Sterling only and drawn on a UK based bank or by Direct bank transfer. For other methods please see www.subramanian.org.uk

Cancellation

Should you be unable to attend, a substitute delegate is welcomed at no extra charge.

12.00 Registration

12.55 Opening remarks Dr G Subramanian.

Emerging Therapeutic Approaches – Antibody, Peptides and Oligonucleotides Chairperson: Dr Rakesh Dixit

1.00 Human single domain antibodies and their application in oncology.

Dr Mike Romonos, CEO; Crescendobiologics, UK.

1.20 Bicyclic peptides to target protein-protein interactions: application to payloads in oncology

Dr Christophe Bonny, CSO; Bicyclitherapeutics.UK.

1.40 Therapeutic Oligonucleotides – progress towards a viable drug platform for tackling intractable targets in oncology.

Dr David Blakey, Chief Scientist Oncology, AstraZeneca, UK.

2.00 Targeted Drug Delivery via XTEN, a protein-based polymer with precisely controlled chemical composition.

Dr Volker Schellenberger, President and CEO, Amunix Operating Inc., USA.

2.20 The Nanobody platform: Opportunity for next generation therapeutics.

Dr Carlo Boutton, Director Technology and Information management, Ablynx, Belgium.

2.40 RNA activation.

Professor Nagy A. Habib, Imperial College, London, UK.

Exploiting the Immune System and stromal cancer therapy

Chairperson: Dr Robert Wilkinson

3.00 Blocking antibodies against a novel immune checkpoint target.

Dr Bas Van Der Woning, arGEN-X BVBA, Belgium.

3.20 Refreshments and Networking.

4.00 Immune activation biologics leading self enhanced war on cancer.

Dr Rakesh Dixit, VP, R&D, Medimmune, USA.

4.20 ErbB-Targeted CAR T Cell Immunotherapy of Cancer: A Strategy to Maximize the Window of Therapeutic Opportunity.

Dr John Maher, Kings College, London, UK.

4.40 Manipulating cancer related inflammation in the tumour microenvironment

Dr Alexander Duncan, CEO., Actigen Ltd, UK.

5.00 Targeting tumor-associated macrophages with a novel anti-CSF-1R antibody in cancer patients.

Dr Klaus Bosslet, Head Discovery oncology Penzberg, Roche Diagnostics gmbH, Germany.

5.20 Targeting the immune system to combat cancer.

Dr Robert Wilkinson, Director of oncology, Medimmune, UK.

Bi-specific Approaches for Therapy Chairperson: Dr Ezio Bonvini

5.40 Advancing bi-specific DART molecules for the treatment of liquid cancers

Dr Ezio Bonvini, SrVP. Macrogenics.Inc., USA.

6.00 Therapeutic applications of bi-specific DARTs for solid tumors: concepts and validation

Dr Paul Moore, Senior Director, Macrogenics. Inc., USA

6.20 Rapid and Systematic Design and Manufacture of Bispecific antibodies and Homogeneous Antibody Drug Conjugates by Cell-free Protein Production

Dr Trevor J.Hallam, CSO, Sutro Biopharm, USA.

6.40 TandAb platform produces bispecific antibodies for killing cancer cells.

Dr Eugene Zhukovsky, CSO, Affimed Therapeutics AG, Germany.

7.00 Single domain antibodies: from conformational sensors to bispecific antibodies for immunotherapy.

Dr Patrik Chames, INSERM, France.